Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.39 |
| ▸ | NPY1R | P25929 | 10/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.39 |
| ▸ | NPY2R | P49146 | 6/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088814 | 0.95 | NPY4R (0.37) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL4082227 | 0.89 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL16468922 | 0.86 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL2193195 | 0.86 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL6240060 | 0.86 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL2183116 | 0.86 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL2194311 | 0.86 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL2192111 | 0.86 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RDPP7 | |
| SCHEMBL4099729 | 0.85 | NPY4R (0.32) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL4082690 | 0.84 | ENPEP (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | NPY4R 1014/4885NPY1R 2090/4885NPY5R 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.